XML 48 R33.htm IDEA: XBRL DOCUMENT v3.26.1
Acquisitions and Divestiture (Tables)
 3 Months Ended
Mar. 28, 2026
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]  
Schedule of Components of Purchase Price and Net Assets Acquired
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)Clario
Purchase price
Cash paid
$5,806 
Debt settled3,180 
Purchase price payable121
Fair value of contingent consideration
110 
Cash acquired
(117)
$9,099 
Net assets acquired
Definite-lived intangible assets
Customer relationships
$2,481 
Product technology
844 
Trade names
19 
Backlog
461 
Goodwill
6,120 
Net other assets/(liabilities)
392 
Contract liabilities
(375)
Deferred tax assets/(liabilities)
(843)
$9,099 
On September 1, 2025, the company acquired, within the Life Sciences Solutions segment, our filtration and separation business, a leading provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications, from Solventum Corporation. The business strengthens the segment’s bioproduction offerings with advanced filtration technologies that improve quality and efficiency across upstream and downstream workflows. In addition, its industrial filtration and membrane solutions will expand our reach into industries including battery, semiconductor and medical device manufacturing. The goodwill recorded as a result of this business combination is not expected to be tax deductible.
The components of the preliminary purchase price and net assets acquired are as follows:
(In millions)Filtration and separation business
Purchase price
Cash paid
$3,939 
Fair value of contingent consideration
(66)
Cash acquired
(9)
$3,865 
Net assets acquired
Property, plant and equipment
$470 
Definite-lived intangible assets
Customer relationships
1,116 
Product technology
388 
Trade names
51 
Goodwill
2,068 
Net other assets/(liabilities)
150 
Deferred tax assets/(liabilities)
(377)
$3,865 
Disposal Groups, Including Discontinued Operations The assets and liabilities of the microbiology business were as follows as of March 28, 2026:
(In millions)
Current assets$231 
Long-term assets758 
Current liabilities72 
Long-term liabilities59